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1. Introduction to vaccinology. 
1.1 Historical background. 
The use of immunization to protect subjects from disease dates back 
hundreds of years.  
Vaccination was tested at the end of the 18th century by Edward 
Jenner, considered the founder of vaccinology in the West in 1796. He 
demonstrated immunity to smallpox[1] by inoculation a 13 year-old-
boy with vaccinia virus (cowpox). Subsequently, the smallpox vaccine 
was developed and a systematic vaccination campaign culminated in 
its global eradication in 1979 (Fig.1). 
      
Fig.1: The timeline of vaccine development until 2010. 
A century later, Louis Pasteur developed methods for attenuating 
bacteria, he produced live attenuated cholera vaccine[2] and inactivated 
anthrax vaccine in humans. All these advances have opened the era of 
vaccinology. In the late 19th century bacterial vaccine development 
proliferated, plague vaccine and the bacillus-calmette-guerin (BCG) 
vaccine (which is still in use today) was created.  
Salmon and Smith developed methods for inactivation of 
microorganisms[3]. The inactivation method with formaldehyde was 
used to develop a vaccine against diphtheria in 1926.  
Viral tissue culture methods led to the advent of the Salk (inactivated) 
polio vaccine and the Sabin (live attenuated oral) polio vaccine[4]. 
Mass polio immunization has greatly reduced the disease caused by 
wild-type virus from thousands of cases per year to only twenty-two 
cases recorded during 2017[5]. 
Attenuated strains of mumps, measles, and rubella were developed for 
addition in vaccines. Measles is actually the next possible target for 
eradication via vaccination. 
New technologies such as the conjugation of proteins to capsular 
polysaccharides and recombinant DNA methods have allowed the 
development of vaccines against bacterial pneumonia, meningitis, 
hepatitis B and recently the vaccine against human papillomavirus 
(HPV)[6-7]. 
Molecular genetics sets nowadays the condition for a bright future for 
vaccinology, including the development of new vaccine delivery 
systems (e.g. viral vectors, DNA vaccines and plant vaccines), new 
adjuvants, the development of more effective tuberculosis vaccines, 
and vaccines against cytomegalovirus (CMV), herpes simplex virus 
(HSV), respiratory syncytial virus (RSV), pandemic influenza, 
staphylococcal disease, streptococcal disease, Shigella, 
schistosomiasis and HIV among others. Therapeutic vaccines may 
also soon be available for autoimmune diseases, allergies and 
addictions. 
The list of illnesses that can be avoided through the administration of 
vaccines is far from being complete, but despite this, there is no doubt 
that vaccines play an important role in reducing mortality and 
morbidity of the most common infectious diseases among which 
meningitis, diphtheria, pertussis, tetanus, measles, mumps, rubella, 
hepatitis B and others[8].  
1.2 The immune system and biological basics of vaccinations. 
The immune system can be divided into two main subsystems, the 
innate system and the adaptive system (Fig. 2). Both interact with 
each other to provide an effective immune response.  
             
Fig. 2. Innate and adaptive immunity scheme. 
The innate immune system is characterized by mechanisms which 
provide a first line of defense against pathogenic agents. These are not 
specific to a particular bacteria, the innate immune cells such as 
leukocyte, phagocytes (neutrophils and macrophages), natural killer 
(NK) are specific for conserved molecular patterns found on all 
microorganisms called PAMPs (Pathogen Associated Molecular 
Patterns) recognized by Pattern recognition receptors (PRRs). This 
prevents the innate immune system from recognizing host cells and 
attacking them. However, the innate immune system responds 
identically to repeated infections from a pathogen, the system does not 
have memory[9]. 
The protective defenses of the innate immune system begin with the 
anatomic barriers such as skin and mucous membranes which prevent 
the entrance of many microorganisms. The skin has an acidic 
environment of pH 3-5 which retards the growth of microorganisms 
and a normal flora which compete with other microorganisms for 
nutrients and attachment sites. Further, the mucus and cilia on the 
mucous membranes aid in trapping microorganisms and propelling 
them out of the body[9]. The innate immune system include  
physiologic barriers as fever, gastric acidity, interferon, lysozyme and 
collectins. The complement pathways and the inflammatory response 
are another essential parts of the innate immune system.  
The actions of the adaptive immune system, in contrast to the innate 
system, are specific to the particular pathogenic agent. This response 
will take longer to occur but the adaptive immune system has 
memory. This means that the adaptive immune system will respond 
more rapidly to that particular pathogen with each successive 
exposure acquiring a better defensive potential[9].  
The adaptive immune system is composed of humoral and cell-
mediated immunity, with the B–cells and the T-cells respectively.  
The humoral immunity fight against extracellular pathogenic agents 
and toxins. B–cells can recognize antigens in their native form, these 
are called T-independent antigens because T-cell activation is not 
required to activate the B–cells. Examples of these antigens are 
lipopolysaccharide, dextran, and bacterial polymeric flagellin. In 
contrast, activation of B–cells with T-helper cell activation results in a 
much better immune response and more effective memory. This long-
term immune response is the type of reaction that is the objective of 
immunizations.  
IgM is the first antibody produced and is a much larger antibody, IgG 
is a better neutralizing antibody, it binds more effectively to the 
antigen and aids in opsonization.  
Other antibodies can be produced by plasma cells include IgD, IgA, 
and IgE. IgD is primarily found as a receptor bound to the surfaces of 
mature B–cells, IgA is found in secretions and IgE is involved in 
allergic reactions and parasitic infections.  
On the other arm of adaptive immunity, cell-mediated immunity 
functions primarily against intracellular pathogens. T-cells develop in 
the thymus and are then, when mature, were released into the 
bloodstream. There are two main types of T-cells, CD4 cells and CD8 
cells. 
CD4 cells or T-helper cells recognize the major histocompatibility 
complex (MHC) II protein and are essential for antibody-mediated 
immunity and in helping B–cells control extracellular pathogens. 
There are two subsets of CD4 cells, Th1 and Th2: Th1 cells help 
promote cell-mediated immunity; Th2 cells help promote antibody-
mediated immunity. 
CD8 cells or T-cytotoxic cells recognize the major histocompatibility 
complex (MHC) I protein, are essential for cell-mediated immunity 
and in helping control of intracellular pathogens. 
T-cells can recognize an antigen that has been processed and 
presented them by antigen-presenting cells. There are two types of 
antigen processing. 
The first involves attaching intracellular antigens along with MHC I 
proteins to the surface of antigen-processing cells. This occurs with 
viral antigens and tumor cells. 
The other type of antigen processing involves attaching extracellular 
antigens along with MHC II proteins to the surface of antigen-
presenting cells. This occurs with bacterial and parasitic antigens.  
1.3 Types of immunization. 
Immunization can be derived from either passive or active means (Fig. 
3). These means that can be from natural or artificial sources. 
 
Fig. 3: Active and passive immunity. 
Natural sources are due to exposure to the environment, humans, and 
animals followed by acquisition and natural eliminations of 
pathogens. In contrast, artificial sources are due to medical 
interventions such as vaccination or antibody inoculation. Vaccination 
is configured as active immunization and has the aim of artificially 
evoking, following the administration of antigens, an immune 
response against the components injected without the manifestation of 
the characteristic symptoms of the disease. This ensures durable 
protection but sometimes requires a latency time of around three 
weeks before it becomes effective, for this reason, the vaccines are 
used for prophylactic purposes on healthy individuals. 
Serotherapy occurs with the transfer to preformed antibodies to an 
unimmunized individual. This subjects so develop a temporary 
immunity to a particular organism or toxin. 
Passive immunization can occur either naturally or artificially. 
Excellent examples of natural passive immunization are the passage of 
maternal antibodies through the placenta to the fetus and the passage 
of these maternal antibodies to the infant through the colostrum and 
milk.  
Excellent examples of artificial passive immunization include the 
administration of pooled human immune gamma globulin and 
antivenin that provide temporary immunity.  
Vaccinations have a dual objective, the defense of the subject and also 
the protection of the community. The herd immunity is reached when 
the percentage of vaccinated is sufficiently high to prevent the spread 
of the pathogen and to guarantee the protection also of the 
unvaccinated subjects. 
1.4 Stimulation of immunity by vaccines. 
The initial identification of pathogen typically is done by the innate 
immune system; although, B-cells may also perform this function. 
This detection starts when the immune system recognizes epitopes on 
antigens.  
Many components of the innate immune system will then activate to 
respond to this challenge. These components will opsonize or bind to 
the agent and aid in its engulfment by antigen-presenting cells such as 
macrophages or monocytes. These antigen-presenting cell will then 
process the antigens from this pathogenic agent and insert the 
processed antigen along with the MHC protein onto the surface on the 
antigen-presenting cell. 
If it is a viral antigen, this will be bound with MHC I protein and 
presented by the antigen-presenting cell to a CD8 cell which will 
trigger cell-mediated immunity. If it is a bacterial or parasitic antigen, 
the antigen will be bound with MHC II protein and presented by the 
antigen-presenting cell to a CD4 cell which will trigger antibody-
mediated immunity. 
1.5 Types of vaccines. 
Vaccines are made using several different processes and according to 
their constitution, are classified into categories. They may contain live 
viruses that have been attenuated, inactivated or killed organisms or 
viruses, inactivated toxins, or merely segments of the pathogen (this 
includes both subunit and conjugate vaccines). 
a. Live attenuated vaccines. 
The most common methods involve the culture of the virus through a 
series of cell cultures or animal embryos (typically chick embryos). 
With each passage, the virus loses partially its ability to replicate in 
human cells and acquire a better replicating capacity in chicken cells.  
When the resulting vaccine is given to a human, it will be unable to 
replicate enough to cause illness, but will still provoke an immune 
response that can protect against future infection. 
One concern that must be considered is the potential for the vaccine 
virus to revert to a form capable of causing disease, mutations that can 
occur when the vaccine virus replicates. 
b. Killed or inactivated vaccines. 
Vaccines of this type are created by inactivating a pathogen, using 
heat or chemicals such as formaldehyde or formalin. These destroy the 
pathogen’s ability to replicate but keeps it “intact” so that the immune 
system can still recognize it.  
Because killed or inactivated pathogens can’t replicate, they can’t 
revert into a virulent form capable of causing disease. However, they 
provide a shorter length of protection than live vaccines and are more 
likely to require boosters to create long-term immunity. Killed or 
inactivated vaccines include the inactivated polio vaccine and the 
seasonal influenza vaccine. 
c. Toxoids. 
Some bacterial diseases are not directly caused by bacterium itself, but 
by the toxin produced. One example is tetanus: symptoms are caused 
by the neurotoxin produced by Clostridium tetani. Immunizations can 
be made by inactivating the toxin that causes disease. As with 
organisms or viruses used in killed or inactivated vaccines, this can be 
done via treatment with a chemical such as formalin, or by using heat 
or other methods. 
Immunizations created using inactivated toxins are called toxoids.  
Toxoid immunizations include tetanus and diphtheria immunizations, 
which are available in a combined form. 
d. Subunit and conjugate vaccines. 
Subunit vaccines use a part of a target pathogen to provoke a response 
from the immune system. This may be done using a specific protein 
isolating from a pathogen and presenting it as an antigen. The 
W135 and Y vaccine and the influenza vaccine are examples of 
subunit vaccines. 
Subunit vaccine can be created using genetic engineering. A gene 
coding for a vaccine protein can be inserted into virus or producer 
cells in culture and then will be harvested and used in the vaccine. 
A vaccine made using genetic engineering is the human 
papillomavirus (HPV) vaccine.  
Conjugate vaccines are similar to recombinant vaccines: they are 
made using a combination of two different components. Conjugate 
vaccines are made using pieces from bacteria. These are chemically 
linked to a carrier protein, and the combination is used as a vaccine 
(Fig. 4).  
         
Fig. 4: Example of protein conjugation to a capsule polysaccharides. 
Conjugate vaccines are used to induce in the subject a more powerful, 
combined immune response. The vaccines currently in use for 
children against Streptococcus pneumoniae infection are made using 
this method. 
1.6 Italian national vaccine prevention plan 2017-2019. 
Italian national vaccine prevention plan and the related vaccination 
calendar have the primary purpose of guaranteeing to the population, 
Carrier protein  Polysaccharides of the capsule 
of a specific serotype 
regardless of their place of residence, income and socio-cultural level, 
the full benefits derived from vaccination, intended both as an 
instrument of individual protection and collective prevention. In 
addition, citizens who fall into target vaccination categories can use it 
for free. 
The objectives identified by the national vaccination prevention plan 
2017-2019 are: 
1. Maintain polio-free status 
2. Reach the free status for measles and rubella 
3. Guarantee the active and free vaccination offer in the indicated 
age groups and in the population considered at risk 
4. Increase the conscious adhesion to vaccination 
5. Fight against inequalities, promoting vaccination intervention in 
marginalized groups of the population 
6. Complete the computerization of the vaccine register at regional 
and national level 
7. Improve the surveillance of preventable diseases by vaccination  
8. Promote in population and in health professionals a vaccination 
culture consistent with the principles of the Italian national 
vaccine prevention plan 
9. Support the sense of responsibility of health professionals and 
full adherence to the prevention plan providing adequate 
sanctions if a behavior of non-compliance is identified 
In addition to vaccinations for which, for years, national immunization 
programs have been planned (diphtheria, tetanus, polio, hepatitis B, 
Haemophilus influenzae b, whooping cough, pneumococcus, measles, 
mumps, rubella, meningococcus C in newborns, HPV in 11-year old 
girls and flu in subjects aged ≥65 years) the national vaccination 
prevention plan 2017-2019 (Fig. 5) includes in the vaccination 
calendar the meningococcal B, rotavirus and varicella vaccinations in 
newborns, HPV in 11-years old males, the tetravalent ACYW135 
meningococcal vaccine and the polio booster with IPV in adolescents 
and pneumococcal (PCV13 conjugate or PPV23 polysaccharide) and 
herpes zoster vaccination in 65 years. 
 
Fig. 5: Italian vaccination calendar plan 2017-2019. 
 
 
 
 
 
 
2. The genus Neisseriae. 
The genus Neisseriae includes many species, among these there are 
Neisseria lactamica, Neisseria mucosa, Neisseria sicca, Neisseria 
flava, Neisseria subflava, nonpathogenic commensals of the upper 
respiratory tract and two pathogenic species: Neisseria gonorrhoeae 
and Neisseria meningitidis identified respectively by Albert Neisser 
(1879) and Albert Weichselbaum (1887). 
Neisseria gonorrhoeae is the etiologic agent of gonorrhea, sexually 
transmitted disease, this is one of the most common contagious 
bacterial illness in humans. 
Neisseria meningitidis exclusively infects humans, is frequently found 
in the nasopharyngeal tract where causes asymptomatic infections 
similar to a colonization of non-pathogenic species of Neisseria (about 
twenty percent are healthy carriers)[10]. 
The levels of colonization are different, especially in relation to age, 
with a peak in adolescence, the incidence of the meningococcal 
disease depends on the geographical area, can reach up to 1000 cases 
per 100,000 per year[11]. 
In the establishment of the carrier state, the adhesion of the 
microorganism to the mucous membranes of the airways is essential; 
in particular conditions, especially susceptible individuals, the 
bacterium spreads in the organism causing serious diseases such as 
meningococcal meningitis, bacteremia and septic arthritis that leads to 
death in ten to fifteen percent of cases or cause permanent disability 
up to twenty percent of affected[12]. The causative agents responsible 
for the transition from the commensal to the pathogenic state are not 
yet completely clarified, it is thought that the expression of virulence 
factors is involved. In fact, some of these genes are not present, not 
expressed or will be expressed differently in strains that do not cause 
pathology. The pathogenic potential can, therefore, be related to the 
presence of pathogen-specific sequences. 
2.1 Neisseria meningitidis: characteristics and epidemiology. 
Neisseria meningitidis is a gram-negative bacterium, asporogenous 
and provided with pili, often cells are found in pairs (diplococci) with 
a diameter of about 0.6-1 µm (Fig. 6). 
 
Fig. 6: Neisseria meningitidis scanning electron microscope. 
Meningococcus grows in an aerobic environment at five to ten percent 
of CO2 and at temperatures between thirty-five and thirty-seven 
degrees centigrade, produces the cytochrome C which is responsible 
for the positivity to the oxidase test. The various Neisseriae strains 
diverge according to the different ability to use simple or a mixture of 
sugars as sources of energy: meningococci ferment both maltose and 
glucose while gonococci exclusively glucose. For cultural isolation, 
enriched soils such as agar-chocolate and GC agar (GonoCoccal Agar) 
are used. 
Compared to all the Neisseriae strains, meningococci have a 
polysaccharide capsule and, according to the different antigens 
presented, are divided into thirteen serogroups (A, B, C, D, 29E, H, I, 
K, L, W135, X, Y, Z). These colonize the nasopharynx but most 
invasive infections, up to ninety-five percent of the total, are caused 
by the strains belonging to serogroups A, B, C, X, Y and W-135[13]. 
Serogroups can be further subdivided into twenty serotypes (based on 
PorB protein antigens), in ten serum subtypes (determined by PorA 
antigens) and in immunotypes based on the immunological properties 
of the outer membrane proteins and of the lipo-oligosaccharide . The 
capsule, composed mainly of polysaccharides, is essential for the 
survival of the bacterium in the bloodstream allowing to resist the 
killing mediated by antibodies or the complement system, to evade 
phagocytosis and to mask the outer membrane proteins, a relevant 
target of the immune response 
The transmission of bacterium occurs through the inhalation of 
infected oropharyngeal drops and the main reservoir is represented by 
carriers, the disease is rarely transmitted by a sick subject. Indeed, 
colonization, even chronic, rarely progresses until the disease, because 
specific antibodies against the colonizing strain are produced in the 
carrier. The disease, on the other hand, is manifested within a few 
days of acquisition of a new meningococcus strain, since immune 
system has not yet been able to produce a sufficient amount of 
neutralizing antibodies. The incidence of the disease is higher in 
children aged between six months and one year and in adolescents 
between fourteen and twenty years. Infections can occur both as 
isolated cases and in form of epidemic outbreaks that take place 
mainly in poor countries in which health facilities are not adequate to 
treat the disease. 
The serogroup A meningococci are the main cause of the epidemics 
described in Africa, China, Nepal, where the disease is endemic; the B 
and C strains predominate in industrialized countries such as the 
United States, Europe and Australia (Fig. 7). 
 
Fig. 7: Epidemiology of meningococcal serogroups in the world. 
In Italy, we have an increased incidence of meningococcal disease, 
232 cases of invasive meningococcal disease (IMD) were reported in 
2016 with an incidence of 0.38 cases per 100,000 (0.23 in 2012, 0.29 
in 2013, 0.27 in 2014 and 0.31 in 2015). An increase of 
meningococcus C infections was observed in Tuscany in 2015-2016, 
such that an extraordinary vaccination campaign was carried out. The 
incidence of the disease is highest in the age group from zero to four 
years with a peak in the first year of life (four cases per one hundred 
thousand) and remains high until age between fifteen and twenty-four 
years (0.3 per 100,000 in 2014 and 0.9 per 100,000 in 2016), 
decreases from the age of twenty-five. Considering the period from 
2011 to 2016 about fifty-three percent of cases manifested as sepsis or 
meningitis/sepsis. 
Examining the spread of serogroups, the B strain is the one most 
frequently identified until 2014 (65%, 51%, 48%, 48% for the years 
2011, 2012, 2013 and 2014, respectively), until 2016 the predominant 
serogroup has become the C strain whereas the data for 2017 and 2018 
show a greater number of cases from B strain. 
The development of meningococcal disease depends on the host's 
immune status. Immunity is usually type-specific and develops within 
the first two decades of life. Meningococcal antibodies, therefore, are 
present in most cases and play an important role in the prevention of 
meningococcal meningitis whose invasive form occurs almost 
exclusively in subjects that do not possess protective levels of 
bactericidal antibodies against the invasive strain. 
If the subject presents signs and symptoms of meningococcal disease, 
the immediate activation of the therapies is necessary; penicillin G, 
chloramphenicol and third-generation cephalosporins are among the 
most effective drugs used to fight the pathogen. 
2.2 Features of the available meningococcal vaccines. 
To date, several vaccines are available for the preventive treatment of 
meningococcal infection. These can be classified into following 
categories. 
a. Polysaccharide-based vaccines. 
Polysaccharide vaccines are composed of purified capsular 
polysaccharides obtained directly from the serogroups of the 
pathogens of interest. The currently administered meningococcal 
vaccine are quadrivalent, these contain capsular polysaccharide 
derived from serogroups A, C, W and Y. Monovalent (for figthing 
serogroups A and C) and trivalent (for serogroups A, C and W) 
vaccines are no longer used. Mencevax (GlaxoSmithKline) is licensed 
for use in Europe whereas Menomune (Sanofi Pasteur) is licensed for 
use in the USA and Canada. Conjugate vaccines elicit longer-lasting 
immune responses.  
 
b. Glycoconjugate vaccines. 
Carbohydrate-based glycoconjugate vaccines use bacterial capsular 
sugars linked to a carrier protein. Three types of carrier proteins have 
been used in vaccines against Neisseria meningitidis: diphtheria 
toxoid (DT), a non-toxic mutant of diphtheria toxoid with a 197 amino 
acid substitution (CRM197), and tetanus toxoid (TT). All of these 
carrier proteins are inactivated and are able to induce B cells and T 
cell-dependent immune responses leading to immune memory.  
c. Monovalent conjugate vaccines. 
There are three commercially available monovalent conjugate 
vaccines licensed for N. meningitidis serogroup C. Two vaccines, 
Meningtec from Pfizer and Menjugate from GlaxoSmithKline, use 
CRM197 as a carrier protein, while the other NeisVac-C by Pfizer 
uses TT. These three vaccines are effective in infants 2 months and 
younger.  
d. Quadrivalent conjugate vaccines. 
There are three licensed quadrivalent vaccines: Menveo 
(GlaxoSmithKline, Brentford, UK) contains CRM197 as a carrier 
protein, Menactra (Sanofi-Pasteur) is a conjugate vaccine of DT with 
and Nimenrix (Pfizer, New York, NY, USA) is a conjugate containing 
TT.  
e. Outer membrane vesicles-based and protein-based vaccines. 
Production of a vaccine against serogroup B has encountered some 
difficulty due to self-antigen concerns. Capsular polysaccharide from 
this serogroup is comprised of α 2-8 linked sialic acid, the same 
linkage of polysialic acid found on the mammalian neural cell 
adhesion molecule.  
OMVs are naturally vesicles released by gram-negative bacteria.  
They contain phospholipids, lipooligosaccharides, and membrane 
proteins. VA-MENGOC-BC is an OMV-based vaccine against N. 
meningitidis serogroup B and C and it was first licensed for use in 
Cuba in 1987.  
The proteins that could be used as a targets for serogroup B 
vaccination were discovered using the reverse vaccinology technique. 
Reverse vaccinology essentially starts with a genomic search for 
potential antigens and the use of recombinant DNA technology to 
produce and test these antigens for suitability (Fig. 8).  
 
Fig. 8: Reverse vaccinology flowchart applied to the production of meningococcal 
B vaccine. 
Vaccine development consists of two fundamental phases: 
1. Characterization of the Neisseria meningitidis genome 
2. Research for proteins that are common to all group B serotypes 
The genomic sequence of the virulent strain Neisseria meningitidis 
MC58, determined by means of shotgun sequencing, revealed more 
than two thousand proteins produced by the bacterium. In the 
identification of potential vaccine antigens, proteins were analyzed 
using bioinformatics algorithms in order to predict their localization 
on the surface of the cell. 
Once the proteins were selected, they were cloned and expressed in E. 
coli, purified and tested on mice to verify their potential ability to 
induce antibody formation. Finally, the serum bactericidal assay 
(SBA) was used to measure antibody activity in killing bacteria by 
activating the complement system. 
Twenty-eight of the proteins tested were able to induce an antibody 
response, unfortunately, not all are present in different meningococcus 
strains. So, for the formulation of a vaccine, it was necessary to 
choose among the most widespread and which had more antigenic 
power. Among these, antigens selected for the vaccine allow broad-
spectrum protection against different meningococcal strains. This 
ability was inferred via SBA or by the ability of antibodies to confer 
passive protection in mouse models. 
This method has led to the licensing of Bexsero (GlaxoSmithKline) 
and Trumenba (Pfizer) vaccines. Bexsero vaccine contains OMV from 
NZ98/254 (an outbreak-specific strain), rNHBA (a recombinant 
Neisseria heparin binding antigen) fusion protein, rNadA 
(recombinant Neisseria adhesin A), rfHbp (a recombinant complement 
factor H binding protein). Instead, Trumenba is composed of two 
antigenic variants of rfHbp factors.  
The reason for the choice of combining different antigens lies in the 
possibility of increasing the coverage spectrum, in order to minimize 
bacterial evasion and avoid the problem of possible selection of 
resistant mutants[16]. 
2.3 Bexsero and Trumenba components. 
In detail, the final formulation of Bexsero®, launched on 14 January 
2013, contains a mix of four main antigenic components: 
• Factor H Binding Protein (fHBP) is also called GNA 1870, it 
binds the complement factor H increasing the ability of the 
microorganism to resist killing mediated by the complement 
system. The protein can be classified into three variants (fHBP-
1, fHBP-2, fHBP-3) and further subdivided into sub-variants 
e.g. fHBP -1.x, fHBP -2.x and fHBP -3.x where x denotes the 
specific sub-variant. In a different nomenclature scheme, sub-
variants are grouped into sub-families, A corresponds to 
variants 2 and 3 and B identifies variant 1. The degree of 
preservation within them ranges from ninety-two to one 
hundred percent, while between variants falls to sixty-three 
percent. This has a negative influence on the degree of cross-
protection, a variant will induce a protective immune response 
against strains that have a similar variant while the response 
will be lower if the strain expresses different variants[14]. The 
sub-variant present in Bexsero® is fHBP 1.1 conjugated to the 
surface protein GNA2091. 
• Neisseria Heparin-Binding Antigen (NHBA), also called GNA 
2132, is a surface lipoprotein able to bind heparin in vitro 
(glycosaminoglycans such as heparan sulfate present in mucosal 
secretions in vivo) through a conserved region rich in arginine, 
this is ubiquitously expressed among meningococci. This 
capacity is related to the increased survival of non-capsulated 
strains in human serum and contributes to the interaction of 
meningococcus with the host cells. Much of the variability of 
protein is found in the amino-terminal region, whereas the 
carboxyl-terminal region is highly conserved. Bexsero® 
contains the variant NHBA peptide 2 (NHBA-2) conjugated to 
the GNA1030 protein and evokes antibodies which are cross-
reactive to the other sub-variants. 
• Neisseria Adhesin A (NadA) is a protein involved in the 
adhesion of the bacterium and in the invasion through the 
epithelial cells of the mucosa, the gene is present in about thirty 
percent of the pathogenic strains and is absent in the strains 
carried by healthy subjects and in other neisseria species[15]. 
There are five variants of NadA (NadA-1,2,3,4,5), in the 
Bexsero® there is NadA-3 sub variant 8 that is able to induce 
cross reactive antibodies against NadA-1, NadA-2 and NadA-3. 
• Outer membrane vesicles (OMVs) of the serogroup B strain 
NZ98 / 254, containing the outer membrane protein PorA P1.4. 
It plays a role in the evasion of the immune system and in the 
antibiotic resistance. 
This vaccine is indicated for active immunization of subjects aged two 
months or more and contains: 50mg of recombinant NHBA protein, 
50mg of recombinant NadA protein, 50mg of recombinant fHbp 
protein, 25mg of outer membrane vesicles strain NZ98/254 which 
contains PorA P1.4 adsorbed on 0,5mg of aluminum hydroxide (Fig. 
9). 
             
    Fig. 9: Schematic representation of the Bexsero vaccine antigens. 
Trumenba® contains two variants fHPB, one for each of the two sub-
families A and B (A05 and B01 respectively). These proteins (also 
known as LP2086) are produced in E. coli and then isolated by 
purification. Each 0.5mL dose of vaccine contains 60µg of both fHBP 
(total 120µg), 0.018mg of polysorbate-80 and 0.25mg of Al3 + in pH6 
buffer. 
This vaccine is indicated for use on subjects aged ten to twenty-five 
years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. The aim of the study. 
In this study we set different objectives, the first is to evaluate the 
degree of oropharyngeal colonization by meningococcus in 
adolescents in Milan, the second is to perform molecular typing to 
verify the presence of hypervirulent strains and the third is to analyze 
the proteins fHBP, NHBA, NadA and PorA present in strains of 
healthy carriers by comparing them to the sequences of the same 
protein contained in the two Bexsero® and Trumenba® vaccines in 
order to estimate the degree of identity. 
For the study we assumed that children and adolescents are the most 
colonized: the first because have immunity defenses that are not yet 
fully developed, others because having repeated opportunities to live 
in close contact with their peers, increasing the risk of being infected. 
Then, oropharyngeal swabs were collected from adolescents attending 
some schools in the Milan area, genomic DNA was extracted from 
them and analyzed by Real-Time PCR in order to identify Neisseria 
meningitidis and its serogroup. 
Subsequently, swabs positive for meningococcus B were processed by 
Multilocus Sequence Typing (MLST) a system of genetic analysis 
based on the polymorphisms present in several constitutively 
expressed genes. Developed by Maiden in 1998 and today the gold 
standard of analysis[17] can also be used for the study of other bacteria. 
We proceed by amplifying the fragments of seven genes, obtaining a 
product of about 500 base pairs, these were sequenced on both strands 
to obtain the nucleotide sequence and were aligned with the reference 
by means of the online database (http://pubmlst.org/neisseria) 
allowing identification of the corresponding allele. The set of the 
seven alleles defines the allelic or sequence type (ST) profile of the 
isolated strain. STs can then be further grouped into clonal complexes 
(CCs) that are defined as a group of STs that have at least four of 
seven loci in common with a central sequence type[18]. This method 
has shown that most of the isolates associated with disease have an 
exact ST and this has allowed to define those hypervirulent strains 
responsible for IMD.  
Finally, the sequences encoding the proteins fHBP, NHBA, NadA and 
PorA were analyzed by amplification and sequencing and were 
compared to the sequences of the proteins contained in the two 
vaccines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Materials and methods. 
4.1 Collection of samples. 
To perform the study, the posterior oropharynx secretions were 
collected from 2560 healthy adolescents aged between fourteen and 
twenty-one (907 males, 35.4%, median age 16.2 years) in the period 
January - March 2016 through the use of swabs Copan 482CE 
containing Amies liquid that maintains the vitality of microorganisms 
(Fig.10).  
 
Fig. 10: Collection swabs with liquid transport. 
Enrollment was voluntary, during the week preceding the swabbing 
students received a brochure providing information regarding 
meningococcal clinical relevance and purpose of the study. Moreover, 
during lesson time, science teachers reinforced the message. 
 Contemporaneously to the execution of throat swab in the medical 
room of the participating school, data regarding age and sex of 
participants were collected and in addition, each student was asked to 
fill a questionnaire to provide information on personal and family 
characteristics to be returned to teachers within a week.  
This study was conducted in compliance with the ethical principles of 
the Helsinki Declaration within the guidelines of Good Clinical 
Pratice. It was approved by the Ethical Committee of the Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. 
Written informed consent was obtained from all subjects and from 
both parents of those under the age of eighteen. 
4.2 Preparation and extraction of DNA from swabs. 
In the laboratory, swabs were labeled with a unique code and 
subsequently were vortexed, centrifuged at 15,000g for 10 minutes to 
homogenate the solution and detach cells present in bristles of 
collection support. Then, 250 µL of amies liquid was incubated at 95 
°C for 10 minutes to kill potentially pathogenic cells.  
Finally, 200 µL of solution was used for extraction by means of High 
Pure PCR Template Preparation Kit (Roche, Cat. n°:11796828001) 
following the manufacturer's instructions. In detail: 
1. Add 5µL of lysozyme to 200µL sample (10 mg/mL in 10nM 
Tris-HCl, pH 8) and incubate for 15 minute at 37 °C 
2. Add 200µL of Binding Buffer and 40µL of proteinase K, shake 
and incubate for 10 minute at 70 °C 
3. Add 100µL of isopropanol and mix 
4. Transfer lysate into purification columns and centrifuge at 
8,000g for 1 minute 
5. Discard eluate and add 500µL of Inhibitor Removal Buffer to 
column, centrifuge at 8,000g for 1 minute 
6. Remove eluate and add 500µL of Wash buffer to column, 
centrifuge at 8,000g for 1 minute 
7. Remove eluate and add 500µL of Wash buffer to column, 
centrifuge at 8,000g for 1 minute 
8. Centrifuge column at maximum speed for 10 seconds 
9. Transfer column into a sterile 1.5mL tube and add 100µL of 
pre-heated Eluition Buffer at 70 °C, centrifuge at 8,000g for 1 
minute to recover DNA 
DNA was then stored at -20 ° C until use. 
4.3 Bacterial identification and serogrouping by Real-Time PCR. 
To carry out identification of meningococci and their serogroups, the 
Real-Time PCR technique was chosen because it is more sensitive 
than the cultural method to identifying a greater number of positive 
cases, probably thanks to the advantage of the molecular method in 
detecting even non vital meningococci unable to grow.  
Real-Time PCR method work with a fluorescent dual-labeled probe 
(TaqMan probe) in addition to the other classic PCR reagents; this 
probe can be displaced and digested by the 5’ exonuclease activity of 
the DNA polymerase upon primer extension. This cause the release of 
fluorophore that excited by laser emits a fluorescence that is measured 
during each PCR cycle; a digital camera collects fluorescence and data 
was so stored on computers (Fig. 11). 
         
Fig. 11: Schematic representation of Real-Time PCR with TaqMan probe. 
The selected primers and probe allow the detection of capsule transfer 
gene (ctrA gene), this protein is localized on the surface of 
meningococci and is common to the different serogroups of Neisseria 
Meningitidis[19] (Fig. 12, Tab. 1). 
 
Fig. 12: Genetic map of the capsule gene complex (cps) of Neisseria Meningitidis. 
The capsule gene is marked in red and the gene for the serogroup in green. 
ctrA 
gene 
oligos 
Sequence (5’ – 3’) Label 
ctrA For GCTGCGGTAGGTGGTTCAA  
ctrA Rev TTGTCGCGGATTTGCAACTA  
ctrA 
Probe 
CATTGCCACGTGTCAGCTGCACAT FAM–
BHQ1 
Tab. 1: Primers used in bacterial identification. 
Amplification was performed in a volume of 25µL containing: 2x 
TaqMan Universal Master Mix (Applied Biosystems), primer at a 
final concentration of 400nM, probe marked in FAM at a final 
concentration of 200nM and 5µL of extracted DNA. Each sample was 
analyzed in triplicate, including in each run a negative control (sterile 
water) and a positive control (DNA extracted from meningococcus). 
Samples were amplified using the ABI 7900HT instrument (Applied 
Biosystems) with following parameters: 95 °C for 10 minutes for 
initial denaturation followed by 45 cycles of two steps denaturation 
and annealing/elongation at 95 °C for 15 seconds and 60 °C for 1 
minute respectively. If no fluorescence signals are detected within the 
40th cycle, the sample is considered negative. Furthermore, the 
specificity of primers was confirmed by specific Real-Time PCR 
using genomic extracts of Neisseria gonorrhoeae, Neisseria 
lactamica, Neisseria sicca, Neisseria flavescens and Neisseria cinerea 
obtained from National Collection of Type Cultures, Central Public 
Health Laboratory. The suitability of sample to molecular analysis has 
been assessed by amplification, using Real-Time PCR, on the human 
RNase P gene in order to understand if the possible failure of the 
bacterium’s detection is due to its absence and not to presence of any 
inhibitors or to a total absence of DNA in extracts indicating a 
swabbing not effective. 
For detection of serogroups, Real-Time PCR was used with primers 
and probes designed to detect specific genes for biosynthesis of the 
capsule of different meningococci, in detail the genes considered 
were: sacB, synD, synE, synG, xcbB and synF 
(https://www.cdc.gov/meningitis/lab-manual/chpt10-pcr.html), (Table 
2). 
Sero-group Capsule type Gene target 
name 
Alternative gene 
names 
A (α1→6)-N-acetyl-D-
mannosamine-1-
phosphate 
sacB  
B (α2→8)- N-
acetylneuraminic acid 
synD siaD, siaDB 
C (α2→9)- N-
acetylneuraminic acid 
synE siaDC 
W135 6-D-Gal(α1→4)-N-
acetylneuraminic 
acid(α2→6) 
synG siaDW 
X (α1→4)-N-acetyl-D-
glucosamine-1-
phosphate 
xcbB  
Y 6-D-Glc(α1→4)-N-
acetylneuraminic 
acid(α2→6) 
synF siaDY 
Tab. 2: Genes used for detection of serogroups. 
Amplification was performed in a volume of 25µL using 2x TaqMan 
Universal Master Mix, primers and specific probes (Tab. 3) and 5 µL 
of DNA extract. 
Thermal cycles are common to all six reactions: 95 °C for 10 minute 
followed by 40 cycles of 95 °C for 1 minute and 60 °C for 1 minute[20-
21]. 
Oligos Sequence (5’ – 3’) Label Final 
concentration 
Nem A For AAAATTCAATGGGTAT
ATCACGAAGA 
 300 nM 
Nem A Rev ATATGGTGCAAGCTG
GTTTCAATAG 
 900 nM 
Nem A 
Probe 
CTAAAAG"T"AGGAAG
GGCACTTTGTGGCATA
AT 
5’ FAM – 
BHQ1 on 
“T”; 3' 
SpC6  
100 nM 
Nem B For TGCATGTCCCCTTTCC
TGA 
 300 nM 
Nem B Rev AATGGGGTAGCGTTG  300 nM 
ACTAACAA 
Nem B 
Probe 
TGCTTATTCCTCCAGC
ATGCGCAAA 
5’ FAM – 
3’ BHQ1 
100 nM 
Nem C For CTTTCCCTGAGTATGC
GAAAAAA 
 900 nM 
Nem C Rev TGCTAATCCCGCCTGA
ATG 
 300 nM 
Nem C 
Probe 
TTTCAATGC”T”AATGA
ATACCACCGTTTTTTT
GC 
5’ FAM – 
BHQ1 on 
“T”; 3' 
SpC6 
100 nM 
Nem W135 
For 
GTGAGGGATTTCCATA
TATATTTA 
 900 nM 
Nem W135 
Rev 
TTGCCATTCCAGAAAT
ATCA 
 900 nM 
Nem W135 
Probe 
TATGGAGCGAATGATT
ACAGTAACTATAA 
5’ FAM – 
3’ BHQ1 
100 nM 
Nem Y For GAGCAGGAAATTTAT
GAGAATACAGA 
 300 nM 
Nem Y Rev CTAAAATCATTCGCTC
CATAT 
 900 nM 
Nem Y 
Probe 
GTATGGTGTACGATAT
CCCTATCCTTGCCTAT
AAT 
5’ FAM – 
3’ BHQ1 
100 nM 
Nem X For TGTCCCCAACCGTTTA
TTGG 
 900 nM 
Nem X Rev TGCTGCTATCATAGCC
GCC 
 900 nM 
Nem X 
Probe 
TGTTTGCCCACATGAA
TGGCGG 
5’ FAM – 
3’ BHQ1 
100 nM 
Tab. 3. Sequences of primers and probes for detection of serogroups and 
concentrations of use. 
 
 
4.4 Bacterial culture 
N. meningitidis grows both on blood agar plate (BAP) and on 
chocolate agar plate (CAP) at 35-37°C with ~5% CO2. Colonies are 
grey and unpigmented on a BAP and appear round, smooth, moist, 
glistening, and convex, with a clearly defined edge, instead on a CAP 
appear large, colorless-to-grey and opaque (Fig. 13).  
     
Fig. 13: N. meningitidis on a BAP plate at left and on a CAP plate at right. 
Isolates should be inspected for the purity of growth and a single 
colony should be re-streaked, when necessary, to obtain a pure 
culture. For the following characterization procedures, testing should 
be performed on 18-24 hour growth from a BAP or CAP in a 
Biosafety Level 2 (BSL-2) environment. 
4.5 Multilocus Sequence Typing, purification, quantification and 
sequencing. 
Many methods of molecular typing are used in epidemiological 
studies for the characterization of pathogens, allowing to analyze the 
genetics of bacterial population and its evolution. These include 
ribotyping, random amplified polymorphic DNA (RAPD), restriction 
fragment length polymorphism (RFLP), multiple-locus variable-
number tandem repeat analysis (MLVA), pulsed-field gel 
electrophoresis (PFGE) and multilocus sequence typing (MLST). 
MLST[22] is a method based on PCR and sequencing of seven house-
keeping genes and allows to define strain analyzed according to the 
allelic profile determined by the nucleotide sequence. For each isolate, 
seven alleles identify the allelic or sequence type (ST) profile of 
bacterium. This technique has numerous advantages, derived above all 
from the use of sequencing method, including: 
1. Directly measure genetic variation  
2. Is adaptable to the analysis of many samples simultaneously  
3. Sequencing data are reproducible and comparable between 
different laboratories 
4. Analysis of sequences can be done remotely and results can be 
viewed on the web 
5. Sequence data can be found on an accessible online database 
(http://pubmlst.org/neisseria) 
6. Information can be obtained by PCR on a clinical sample 
The sequenced gene portions have a size of about 500 base pairs and 
those considered are: Putative ABC transporter (abcZ), Adenylate 
kinase (adk), Shikimate dehydrogenase (aroE), Fumarate 
dehydrogenase (fumC), Glucose-6-phosphate dehydrogenase (gdh), 
Pyruvate dehydrogenase subunit (pdhC) and Phosphoglucomutase 
(pgm). Several pairs of primers are used, one is useful for fragment 
amplification (Tab. 4) and the second pair is used in sequencing 
reaction (Tab. 5) (Fig. 14). 
Gene name Primer’s 
name 
Sequence (5’ – 3’) 
abcZ abcZ-P1C TGTTCCGCTTCGACTGCCAAC 
abcZ-P2C TCCCCGTCGTAAAAAACAATC 
adk adk-P1B CCAAGCCGTGTAGAATCGTAAACC 
adk-P2B TGCCCAATGCGCCCAATAC 
aroE aroE-P1B TTTGAAACAGGCGGTTGCGG 
aroE-P2B CAGCGGTAATCCAGTGCGAC 
fumC fumC-P1B TCCCCGCCGTAAAAGCCCTG 
fumC-P2B GCCCGTCAGCAAGCCCAAC 
gdh gdh-P1B CTGCCCCCGGGGTTTTCATCT 
gdh-P2B TGTTGCGCGTTATTTCAAAGAAGG 
pdhC pdhC-P1B CCGGCCGTACGACGCTGAAC 
pdhC-P2B GATGTCGGAATGGGGCAAACA 
pgm pgm-P1 CTTCAAAGCCTACGACATCCG 
pgm-P2 CGGATTGCTTTCGATGACGGC 
Tab. 4: Amplification primers. 
 
Gene name Primer’s 
name 
Sequence (5’ – 3’) 
abcZ abcZ-S1A AATCGTTTATGTACCGCAGR 
abcZ-S2 GAGAACGAGCCGGGATAGGA 
adk adk-S1A AGGCWGGCACGCCCTTGG 
adk-S2 CAATACTTCGGCTTTCACGG 
aroE aroE-S1A GCGGTCAAYACGCTGRTK 
aroE-S2 ATGATGTTGCCGTACACATA 
fumC fumC-S1 TCCGGCTTGCCGTTTGTCAG 
fumC-S2 TTGTAGGCGGTTTTGGCGAC 
gdh gdh-S3 CCTTGGCAAAGAAAGCCTGC 
gdh-S4C RCGCACGGATTCATRYGG 
pdhC pdhC-S1 TCTACTACATCACCCTGATG 
pdhC-S2 ATCGGCTTTGATGCCGTATTT 
pgm pgm-S1 CGGCGATGCCGACCGCTTGG 
pgm-S2A GGTGATGATTTCGGTYGCRCC 
Tab. 5: Sequencing primers. 
 
    
Fig. 14: Schematic MLST analysis. 
 
Amplification was performed in a volume of 50 µL using 10x 
AmpliTaq Gold® 360 Buffer, 1 µL of both primers (initial 
concentration 10 µM), 6 µL of Magnesium MgCl2 (initial 
concentration 25mM), 1 µL of dNTPs (initial concentration 10mM), 
2.5U of Taq Polymerase and 5 µL of extracted DNA. Thermocycler 
used is Applied Biosystems 2720 Thermal Cycler, cycles for 
amplification are common for all seven reactions and consist of: 94 °C 
for 5 minute, followed by 40 cycles of 94 °C for 1 minute, 55 °C for 1 
minute and 72 °C for 1 minute, 72 °C for 5 minute and 4 °C at the end 
of the reaction. In each one a positive and a negative amplification 
control have been included. 
The products are visualized by 1% agarose gel electrophoresis treated 
with Syber Safe (Thermo Fisher Scientific) intercalating the DNA and 
with the molecular weight marker 1kb Plus DNA Ladder (Thermo 
Fisher Scientific) that allows to discriminate amplicons ranging from 
100 to 12.000 base pairs. Once the products of interest have been 
identified, these are recovered from gel by cutting with a sterile 
bistoury and placed in a 1,5mL tube for following purification phase 
(Fig.15). 
  
Fig. 15: Gel electrophoresis and cutting PCR products. 
 
The fragment is purified using the PCR clean-up Gel extraction kit 
(Macherey-Nagel), in detail: 
1. Determine the weight of gel’s fragment 
2. Add 200µL of NTI buffer per 100mg of gel 
3. Incubate sample for 5-10 minute at 50 °C, shake every 3 minute 
4. Transfer sample above the column and centrifuge at 11,000g for 
30 seconds, discard the eluate 
5. Add 700µL of NT3 buffer, to perform wash, and centrifuge at 
11,000g for 30 seconds, then discard eluate 
6. Add 700µL of NT3 buffer, to perform wash, and centrifuge at 
11,000g for 30 seconds, then discard eluate 
7. Centrifuge at 11,000g for 1 minute in order to eliminate 
washing residues from filter 
8. Place column in a sterile 1.5 mL tube, add 30µL of NE buffer 
(elution) and incubate at room temperature for 1 minute 
9. Centrifuge at 11,000g for 1 minute to recover DNA 
10. Store DNA at -20 until use 
Following the purification of fragments we proceeded with their 
quantification by means of the Quant-iT dsDNA Assay Kit, High 
Sensitivity (Thermo Fisher Scientific) and the Qubit 3 Fluorometer 
instrument, in detail: 
1. Prepare working solution consisting of 199µL of HS Buffer and 
1µL of dye for each sample to be tested (in duplicate) including 
two standard curve points 
2. Two curve points consisting of 190µL of working solution and 
10µL of DNA supplied with the kit (0-10ng/µL) 
3. Prepare samples by adding 2µL of DNA into 198µL of working 
solution 
4. Vortex and incubate in the dark for 2 minute 
5. Calibrate instrument with two standard curve points and then 
read quantities, in nanograms per microliter, of DNA eluted 
from gel 
After this quantification, samples are prepared for sending to GATC, a 
company based in Germany, which was responsible for sanger 
sequencing reactions. The samples are prepared in order to send: 
• 5 µL of PCR product (20-80ng/µL) 
• 5 µL of primer (concentrated 5µM) 
Two sequence reactions, one with the forward primer and one with the 
reverse, were performed. Once sequences were obtained, they were 
assembled using the Sequencher 4.1.4 software and corrected, 
consensus sequence was submitted to the online database 
(http://pubmlst.org/neisseria) in order to obtain the number of the 
corresponding allele. Once obtained all numbers of alleles (seven 
genes analyzed) these were submitted into the same database to obtain 
sequence type and clonal complex of strain examinated. 
4.6 Analysis of vaccine proteins. 
The analysis of nucleotide sequences and predicted amino acid 
sequences of proteins present in meningococcus B strains allows to 
estimate the degree of identity between protein encoded by the 
bacterium and the protein used in the formulation of the vaccine. So 
we proceeded with the analysis of gene sequences of fHBP, NHBA, 
NadA and PorA, by PCR amplification, gel electrophoresis, 
purification, quantification of DNA and sequencing following method 
published by Lucidarme[23]. The instrument used is Applied 
Biosystems 2720 Thermal Cycler, primers are shown in Tab. 6 and the 
amplification conditions in Tab. 7. 
Target Primer use 
(direction) 
Primer 
identifier 
Sequence (5’ – 3’) 
 
fHBP 
PCR/Seq 
(fwd) 
gna1870F TGACCTGCCTCATTGATGC 
PCR/Seq 
(rev) 
gna1870R CGGTAAATTATCGTGTTCG
GACGGC 
PCR/Seq 
(rev) 
gna1870v3
R 
CGTGCCGTCGTGTCCTAG 
Seq (fwd) gna1870S2 CAAATCGAAGTGGACGGG
CAG 
Seq (fwd) gna1870S3 TGTTCGATTTTGCCGTTTCC
CTG 
 
NHBA 
PCR/Seq 
(fwd) 
gna2132F GGCGTTCAGACGGCATATT
TTTACA 
PCR/Seq 
(rev) 
gna2132R GGTTTATCAACTGATGCGG
ACTTGA 
Seq (fwd) gna2132S2 GCGGACACGCTGTCAAAAC
C 
Seq (fwd) gna2132S4 GGCGTTCTGCACGGTCGAG
G 
Seq (fwd) gna2132S5 ATGGGTACGCAAAAATTCA
A 
Seq (rev) gna2132S7 AATGCAGTACTTCGCCGTT
GT 
Seq (rev) gna2132S8 CCTCGACCGTGCAGAACGC
C 
Seq (rev) gna2132S9 CCGCACCGCCATTGCCTGT
A 
 
nadA 
PCR/Seq 
(fwd) 
nadAF GTGGACGTACTCGACTACG
AAGG 
PCR/Seq 
(rev) 
nadAR CGAGGCGATTGTCAAACCG
TTC 
PCR/Seq 
(fwd) 
nadAintF TATGTAAACAAACTTGGTG
GGG 
PCR/Seq 
(rev) 
nadAintR GAAATAGAAAAGTTAACA
ACCAAGTT 
Seq (fwd) nadAS1 TATGTAAACAAACTTGGTG
GGG 
Seq (fwd) nadAS2 GAAATAGAAAAGTTAACA
ACCAAGTT 
Seq (fwd) nadAS3 GACATCAAAGCTGATATCG
CTAC 
Seq (rev) nadAS4 TTTCGAGGTGGCGCGTTCG
GG 
Seq (rev) nadAS5 GTAGCGATATCAGCTTTGA
TGTC 
Seq (rev) nadAS6 CTTGGTTGTTAACTTTTCTA
TTTC 
porA PCR (fwd) 210 ATGCGAAAAAAACTTACCG
CCCTC 
PCR (rev) 211 AATGAAGGCAAGCCGTCA
AAAACA 
porA 
(VR1) 
Seq (fwd) P3 CAAAGCCGGCGTGGAAG 
Seq (rev) 103L AACGGATACGTCTTGCTC 
porA 
(VR2) 
Seq (fwd) 8U TCCGTACGCTACGATTCTC
C 
Seq (rev) 122L GGCGAGATTCAAGCCGCC 
Tab. 6: Primers used in amplification and sequencing reactions. 
 
Target Denaturation Annealing Extension N° of 
cycles 
fHBP 96°C, 30 sec 63°C, 30 sec 72°C, 1 min 30 
NHBA 96°C, 30 sec 57°C, 30 sec 72°C, 1 min 30 
nadA 96°C, 30 sec 56°C, 30 sec 68°C, 1min 20 sec 30 
porA 94°C, 1 min 68°C, 1 min 72°C, 2 min 30 
Tab. 7: PCR conditions. 
 
Sequencing was performed at GATC and forward and reverse 
sequences were assembled with the software Sequencher 4.1.4, the 
obtained sequences were used to query the online database 
(http://pubmlst.org/neisseria) to have: the number of the nucleotide 
allele, the number of the corresponding peptide and the degree of 
identity towards the proteins contained in the two vaccines. 
 
 
 
 
 
 
 
5. Results. 
Real-Time PCR screening of 2560 subjects allowed to identify 135 
meningococcal carriers (5.3%). Among these, serogroup B is the most 
frequently detected (n = 58, 43%) followed by serogroup Y (n = 32, 
23.7%), by serogroup C (n = 7, 5.2%), by serogroup W135 (n = 6, 
4.4%) and by serogroup X (n = 5, 3.7%), none belongs to serogroup 
A. In 27 cases none of the genes for capsule synthesis were detected 
(Fig. 16). No difference in Men carriage prevalence according to the 
type of school, age and gender were evidenced.  
                 
Fig. 16: Distribution of serogroups in the analyzed samples. 
On samples positive for meningococcus B we proceeded with MLST 
analysis performed by PCR, gel electrophoresis and sequencing of 
products.  
Amplification of abcZ gene provides a product that measures 897 base 
pairs and the next internal fragment to be sequenced measure 515 base 
pairs (Fig. 17, Fig. 18). 
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Fig. 17: Blast of abcZ primers on N. meningitidis MC58 genome. 
         
Fig. 18. Gel electrophoresis photo’s of abcZ amplification. 
The amplification of adk gene provides a product that measures 707 
base pairs and the next internal fragment to be sequenced measure 511 
base pairs (Fig. 19, Fig. 20). 
Fig. 19: Blast of adk primers on N. meningitidis MC58 genome. 
  
Fig. 20. Gel electrophoresis photo’s of adk amplification. 
The amplification of aroE gene provides a product that measures 834 
base pairs and the next internal fragment to be sequenced measure 636 
base pairs (Fig. 21, Fig. 22). 
Fig. 21: Blast of aroE primers on N. meningitidis MC58 genome. 
        
Fig. 22. Gel electrophoresis photo’s of aroE amplification. 
The amplification of fumC gene provides a product that measures 859 
base pairs and the next internal fragment to be sequenced measure 529 
base pairs (Fig. 23, Fig. 24). 
Fig. 23: Blast of fumC primers on N. meningitidis MC58 genome. 
           
Fig. 24. Gel electrophoresis photo’s of fumC amplification. 
The amplification of gdh gene provides a product that measures 676 
base pairs and the next internal fragment to be sequenced measure 597 
base pairs (Fig. 25, Fig. 26). 
Fig. 25: Blast of gdh primers on N. meningitidis MC58 genome. 
  
Fig. 26. Gel electrophoresis photo’s of gdh amplification. 
The amplification of pdhC gene provides a product that measures 817 
base pairs and the next internal fragment to be sequenced measure 583 
base pairs (Fig. 27, Fig. 28). 
Fig. 27: Blast of pdhC primers on N. meningitidis MC58 genome. 
Fig. 28. Gel electrophoresis photo’s of pdhC amplification. 
The amplification of pgm gene provides a product that measures 1338 
base pairs and the next internal fragment to be sequenced measure 492 
base pairs (Fig. 29, Fig. 30). 
 Fig. 29: Blast of pgm primers on N. meningitidis MC58 genome. 
 
Fig. 30. Gel electrophoresis photo’s of pgm amplification. 
Data obtained from sequencing are used to query online MLST 
database (https://pubmlst.org/neisseria/) to obtain the number of the 
corresponding allele. Eleven clonal complexes were identified, four 
samples (6.9%) present a combination of alleles for which no clonal 
complex can be assigned from the online database (Tab. 8). 
Clonal complex 
(CCs) 
N° of identification 
(%) 
ST-162 12 (20.7) 
ST-865 12 (20.7) 
ST-
41/44/Lineage 3 
11 (19) 
ST-35 6 (10.3) 
ST-32/ET-5 4 (6.9) 
ST-269 3 (5.2) 
ST-213 2 (3.4) 
ST-198 1 (1.7) 
ST-461 1 (1.7) 
ST-549 1 (1.7) 
ST-750 1 (1.7) 
Unassigned CCs 4 (6.9) 
Tab. 8: Distribution of clonal complexes in samples. 
 
Generally, clonal complexes associated with hypervirulent strains 
have been found among all serogroups responsible for IMD, for 
serogroup B clonal complexes associated with higher virulence are: 
ST-41/44 / Lin3, ST-32 / ET-5, ST-11 / ET-37, ST-8 / Cluster A4[24] 
and ST-269 recently added[25]. In analyzed subjects, there are 
hypervirulent strains among which ST-41/44 / Lineage 3 is more 
represented (19%). 
 
Data analysis of proteins included in two vaccines show that, 
regarding fHbp gene, all strains except 3 harbored fHbp alleles 
represented by a total of 31 sub-variants: 18 in variant 1 (v.1 n=25; 
45.4%), 8 in variant 2 (v.2 n=25; 45.4%) and 5 in variant 3 (v.3, n=5; 
9.1%). Variants 1 and 2 were mainly present in the ST-162, ST-
41/44/Lin3 and ST-865 CCs instead variant 3 was primarily found in 
ST-269 CC (Fig. 31). 
Fig. 31: Distribution of fHbp variants by the clonal complex. 
Among the 18 sub-variants in variant 1: gene for fHbp sub-variant 
included in 4CMenB vaccine (fHbp 1.1) and the sub-variant included 
in MenB fHbp vaccine (fHbp 1.55) was not identified in any strains 
whereas, regarding the 5 sub-variant in variant 3, the gene for fHbp 
sub-variant included in MenB.fHbp vaccine (fHbp 3.45) was detected 
in one strain. Data concerning percentage of amino acid identity 
shows that for detected fHbp sub-variants 1 identity towards 4CMenB 
sub-variant varies from 90.9% to 99.2% (median: 96.1%) instead that 
against MenB fHbp varies from 87.7% to 93.1% (median: 89.2%). 
The identity regarding detected sub-variant 3 towards the MenB fHbp 
varies from 93.7% to 100% (median: 97.6%) (Fig. 32-33).  
 
Fig. 32. Boxplot fHbp percentage identity. 
 
 Fig. 33. Phylogenetic analysis of identified fHBP. 
The gene for NHBA protein was found in all strains except for 6 
(10.3%) and 21 sub-variants were identified, the gene for NHBA 
protein included in the 4CMenB vaccine (sub-variant 2) was not found 
in any strains. The sequencing data regarding NHBA gene shows that 
the sub-variants most common were: 908 (n=10, 19.2%) in ST-865 (9 
strain) and in ST-549; 879 (n=10, 19.2%) in ST-162 (9 strain) and ST-
865; 21 (n=6, 11.5%) in ST-35 (4 strain) and in ST-269 (2 strain). The 
sub-variants had an amino acid identity towards protein included in 
the 4CMenB vaccine that varying from 71.3% to 99.8% (median: 
76%) (Fig. 34-35). Among strains without NHBA gene, 5 had a gene 
for fHbp protein variant 1 and 1 a gene for fHbp protein variant 2. 
 
Fig. 34. Boxplot NHBA percentage identity. 
 
 Fig. 35. Phylogenetic analysis of identified NHBA. 
PorA proteins were identified in 53 out of 58 (91.4%) studied MenB 
strains and 22 porA sub-types were identified. The protein included in 
the 4CMenB vaccine (P1.4) was identified in 4 strains belonging to 
ST-162 (3 strain) and ST-41/44 Lin3 (1 strain). The amino acid 
identity between studied porA proteins and those were included in the 
4CMenB vaccine was not less than 88.1% (median: 91.8%) (Fig. 36-
37).  
 
Fig. 36: Boxplot PorA percentage identity. 
 
 
 Fig. 37: Phylogenetic analysis of identified PorA. 
The gene for NadA proteins was not detected in any of the 58 studied 
strains. 
6. Conclusion 
In this study was found that, in adolescent living in Milan, Neisseria 
meningitidis serogroup B was the most commonly carried followed by 
serogroup Y. This finding is in agreement with was reported in recent 
studies carried out in Europe where MenB is the most frequently 
identified meningococcus in the pharynx of both healthy individuals 
and patients with IMD[26-27-28]. This was expected because the 
introduction of MenC conjugate vaccine has significantly reduced 
MenC carriage and circulation evidencing the role of MenB in 
carriage and disease. In northern Italy, MenC vaccine coverage in 
children younger than 24 months is about 90%[29] and this could 
explain the low detection of MenC into studied population. On the 
contrary, in Italy, 4CMenB vaccine has been recently included in 
official vaccination schedule and recommended only for infants and 
toddlers, although a possible inclusion for the adolescent in next 
future was suggested[30]. This means that no effects for MenB 
vaccination may have occurred, on the other hand in Lombardy, the 
region of Italy where this study was performed, the incidence of 
MenB invasive disease has remained substantially unmodified in the 
last 10 years (i.e. around 4 cases out of 100,000)[31]. 
The genetic characteristics of MenB strains identified in this study are 
quite similar to those identified in a previous study performed several 
years earlier in a similar population living in the same geographic 
area[23]. This seems to confirm that, despite the high incidence of 
genetic exchange, meningococcal strains are relatively stable[13]. 
In analyzed strains was found that a great number could be included in 
some of the clonal complexes frequently associated with bacterial 
hypervirulence and development of IMD, such as ST-41/44 Lin3 and 
ST-32, this suggests a potential virulence of meningococcal strains 
carried by the study population. The MenB vaccines presently 
licensed could have theoretically induced the production of antibodies 
effective against the greatest part of identified meningococci. 
Trumenba® contains two sub-variants of bacterial fHbp proteins and in 
studied strains 1 had the exactly sub-variant (fHbp 3.45) included in 
this vaccine. Bexsero® contains a variant of fHbp proteins (fHbp 1.1), 
a NadA-3 component, a variant of NHBA protein (sub-variant 2) and 
PorA P1.4 and in studied strain 4 had a protein that exactly matches 
with PorA included in the vaccine. In analyzed bacteria, the gene for 
NadA was never found as frequently occurs in carried stains[32]. These 
findings show that 1 subject is fully covered by Trumenba® vaccine 
and 4 subjects are fully covered by Bexsero® [33]. In all of the other 
cases, amino acid identity seem to suggest that this two vaccines could 
evoke antibodies able to eliminate carried strains. Indeed, for fHbp, 
each variant family (1, 2 or 3) induce a strong protective immune 
response against strains carrying homologous alleles but are 
ineffective against strains that express distantly related variant. 
Regarding NHBA, preclinical studies suggest that antibodies elicited 
against the vaccine peptide are cross-protective against strains 
expressing different NHBA peptides. Finally three main NadA 
variants (NadA-1, NadA-2, NadA-3) show highly conserved 
sequences and produce cross-bactericidal activity[18]. Therefore these 
vaccines could theoretically induce the production of antibodies 
effective against the greatest part of the identified MenB strains, 
although with slight differences between them . 
Elimination of carriage seems essential to maximize the efficacy of a 
meningococcal vaccine. A relevant part of the positive effects 
obtained with the use of MenC vaccine was due to population 
immunity induced by the reduction of carriage and pathogen 
transmission[34]. However, the potential positive effect of both MenB 
vaccines suggested should be considered with caution because the 
only presence of genes encoding proteins included in vaccines was 
studied. Gene expression was not evaluated and it has been 
demonstrated that MenB vaccines are theoretically effective when the 
invasive meningococcal strain is able to produce one or more of 
vaccine components at a concentration higher than the minimum 
required for the bactericidal protective activities of antibodies[35-36]. 
The meningococcal antigen typing system (MATS) is a suitable 
method to predict the susceptibility of individual MenB strains to be 
killed by bactericidal antibodies elicited by vaccination, this allows a 
qualitative and quantitative evaluation of the antigens expressed on 
the surface of meningococcus. This is a modified ELISA assay that 
quantifies expression and the level of matching with the 
corresponding antigen (fHbp, NHBA and NadA) included in the 
vaccine. 
In another study authors reported that 3 months after dose two of 
4CMenB vaccination, subjects had a 26.6% lower carriage of any 
meningococcal strain including capsular groups BCWY[29]. This 
findings is not surprising because proteins included in both vaccines 
are not exclusive of MenB but are present in meningococcal strain 
regardless of the serogroup. 
Therefore, monitoring carriage remains essential to evaluate MenB 
circulation but a long-term studies will be necessary to evaluate the 
effects on the carriage and the final efficacy of both new MenB 
vaccines. 
 
7. Papers published during PhD 
During these years of PhD I participate in conducting several 
epidemiological studies focused in particular to identify, by molecular 
methods, different pathogens both bacteria or viruses cause of disease or 
carried by subject in order to understand the long term efficacy of vaccines 
or to advise, for particular categories of population, a booster vaccination.  
These studies have generated some papers that I describe below: 
1. Interaction between Streptococcus pneumoniae and Staphylococcus 
aureus in paediatric patients suffering from an underlying cronic 
disease. 
Esposito S, Marseglia GL, Colombo C, Iughetti L, Terranova L, Ierardi V, 
Gambino M, Principi N; Italian Pneumococcal Study Groups on Asthma, 
Cystic Fibrosis and Diabetes.  
Int J Immunopathol Pharmacol. 2015 Dec;28(4):497-507.  
doi: 10.1177/0394632015601486. 
Abstract: 
Little is known about the interaction between Streptococcus 
pneumoniae and Staphylococcus aureus in school-age children and 
adolescents suffering from an underlying chronic disease. To increase 
our knowledge in this regard, an oropharyngeal swab was obtained 
from school-age children and adolescents suffering from asthma (n = 
423), cystic fibrosis (CF) (n = 212) and type 1 diabetes mellitus 
(DM1) (n = 296). S. pneumoniae detection and serotyping were 
performed using a real-time polymerase chain reaction, and S. aureus 
detection was performed using the RIDAGENE MRSA system. 
Among asthmatic, CF and DM1 patients, both pathogens were 
identified in 65/423 (15.4%), 21/212 (9.9%) and 62/296 (20.9%) 
children, respectively; S. pneumoniae alone was identified in 127/434 
(30.0%), 21/212 (9.9%) and 86/296 (29.1%), respectively; S. aureus 
alone was identified in 58/434 (13.7%), 78/212 (36.8%) and 49/296 
(16.6%), respectively. S. pneumoniae colonisation rates were higher in 
younger children and declined with age, whereas the frequency of S. 
aureus colonisation was quite similar in the different age groups. 
Among asthmatic and CF patients aged 6-9 years, S. aureus carriage 
was significantly higher in children who were positive for S. 
pneumoniae (P <0.05). No significant association emerged between S. 
aureus carriage and carriage of S. pneumoniae serotypes included in 
the pneumococcal conjugate vaccines (PCVs). This study shows for 
the first time that school-age children and adolescents with asthma, 
CF and DM1 are frequently colonised by S. pneumoniae and S. aureus 
and that no negative relationship seems to exist between these 
pathogens. Moreover, the supposed protection offered by PCV 
administration against S. aureus colonisation was not demonstrated. 
2. Streptococcus pneumoniae pharyngeal colonization in school-age 
children and adolescents with cancer. 
Principi N, Preti V, Gaspari S, Colombini A, Zecca M, Terranova L, 
Cefalo MG, Ierardi V, Pelucchi C, Esposito S.  
Hum Vaccin Immunother. 2016;12(2):301-7.  
doi: 10.1080/21645515.2015.1090071. 
Abstract: 
Patients with cancer, particularly those with hematologic 
malignancies, are at an increased risk of invasive pneumococcal 
disease (IPD) and they are included in the list of subjects for whom 
pneumococcal vaccination is recommended. The main aim of this 
study was to evaluate Streptococcus pneumoniae colonization in 
school-aged children and adolescents with cancer to determine the 
potential protective efficacy of 13-valent pneumococcal conjugate 
vaccine (PCV13). An oropharyngeal swab was obtained from 277 
patients (age range 6-17 years) with cancer during routine clinical 
visits and analyzed for S. pneumoniae using real-time polymerase 
chain reaction. S. pneumoniae was identified in 52 patients (18.8%), 
including 47/235 (20.0%) with hematologic malignancies and 5/42 
(11.9%) with solid tumors. Colonization declined significantly with an 
increase in age (odds ratio [OR] 0.34, 95% confidence interval [CI] 
0.16-0.71, and OR 0.30, 95% CI 0.11-0.82 in children aged 10-14 and 
≥15 years, respectively, as compared to those <10 years). Carriage 
was more common among patients with leukemia or lymphoma than 
in children with solid tumors. Co-trimoxazole prophylaxis was 
significantly associated with reduced pneumococcal carriage (OR 
0.41, 95% CI 0.19-0.89). A total of 15/58 (25.9%) and 26/216 (12.0%) 
children were colonized by PCV13 serotypes among cancer patients 
previously vaccinated and not vaccinated with 7-valent pneumococcal 
conjugate vaccine (PCV7), respectively. In conclusion, this study 
indicates that children and adolescents with cancer are frequently 
colonized by S. pneumoniae. Because most of the carried serotypes 
are included in PCV13, this vaccine is presently the best solution to 
reduce the risk of IPD in these patients. 
3. Streptococcus pneumoniae colonization in children and adolescent 
with asthma: impact of the heptavalent pneumococcal conjugate 
vaccine and evaluation of potential effect of thirteen-valent 
pneumococcal conjugate vaccine. 
Esposito S, Terranova L, Patria MF, Marseglia GL, Miraglia del 
Giudice M, Bodini A, Martelli A, Baraldi E, Mazzina O, Tagliabue C, 
Licari A, Ierardi V, Lelii M, Principi N. 
BMC Infect Dis. 2016 Jan 12;16:12. doi: 10.1186/s12879-016-1335-3. 
Abstract: 
Background: 
The main aim of this study was to evaluate Streptococcus pneumoniae 
carriage in a group of school-aged children and adolescents with 
asthma because these results might indicate the theoretical risk of 
invasive pneumococcal disease (IPD) of such patients and the 
potential protective efficacy of the 13-valent pneumococcal conjugate 
vaccine (PCV13). 
Methods: 
Oropharyngeal samples were obtained from 423 children with 
documented asthma (300 males, 70.9%), and tested for the autolysin-
A-encoding (lytA) and the wzg (cpsA) gene of S. pneumoniae by 
means of real-time polymerase chain reaction. 
Results: 
S. pneumoniae was identified in the swabs of 192 subjects (45.4%): 
48.4% of whom were aged <10 years, 46.9% aged 10-14 years, and 
4.7% aged ≥15 years (p < 0.001). Carriage was significantly less 
frequent among the children who had received recent antibiotic 
therapy (odds ratio [OR 0.41]; 95% confidence interval [95% CI] 
0.22-0.76). Multivariate analyses showed no association between 
carriage and vaccination status, with ORs of 1.05 (95% CI 0.70-1.58) 
for carriers of any pneumococcal serotype, 1.08 (95% CI 0.72-1.62) 
for carriers of any of the serotypes included in 7-valent pneumococcal 
conjugate vaccine (PCV7), and 0.76 (95% CI 0.45-1.28) for carriers of 
any of the six additional serotypes of PCV13. Serotypes 19 F, 4 and 9 
V were the most frequently identified serotypes in vaccinated subjects. 
Conclusions: 
These results showed that carriage of S. pneumoniae is relatively 
common in all school-aged children and adolescents with asthma, 
regardless of the severity of disease and the administration of PCV7 in 
the first years of life. This highlights the problem of the duration of 
the protection against colonisation provided by pneumococcal 
conjugate vaccine, and the importance of re-colonization by the same 
pneumococcal serotypes included in the previously used vaccine. 
4. Pneumococcal colonization in older adults. 
Esposito S, Mari D, Bergamaschini L, Orenti A, Terranova L, 
Ruggiero L, Ierardi V, Gambino M, Croce FD, Principi N. 
Immun Ageing. 2016 Jan 12;13:2. doi: 10.1186/s12979-016-0057-0.  
Abstract: 
Background: 
Little is known about pneumococcal carrier states in older adults. The 
main aim of this study was to evaluate pneumococcal colonization 
patterns among older adults in two centres in Milan, Italy, before the 
widespread use of the 13-valent pneumococcal vaccine (PCV13) in 
this age group, to investigate demographic and clinical features that 
are associated with pneumococcal colonization and to estimate the 
potential coverage offered by PCV13. 
Results: 
Among 417 adults ≥65 years old (171, 41.1 %, ≥75 years), 41 (9.8 %) 
were pneumococcal carriers. Univariate and multivariate analyses 
revealed that pneumococcal colonization was significantly less 
common among individuals with underlying co-morbidities than 
among those without (odds ratio [OR] 0.453, 95 % confidence interval 
[CI] 0.235-0.875, p = 0.018; adjusted OR 0.503, 95 % CI 0.255-0.992, 
p = 0.047). Moreover, among these patients, those with cardiac disease 
had a significantly lower risk of colonization (OR 0.308, 95 % CI 
0.119-0.795, p = 0.015; adjusted OR 0.341, 95 % CI 0.13-0.894, 
p = 0.029). Only one vaccinated subject who received 23-valent 
polysaccharide pneumococcal vaccine (PPV23) was colonized. 
Twenty-five (89.3 %) of the subjects who were <75 years old and 9 
(75.0 %) of those who were ≥75 years old were colonized by at least 
one of the serotypes that is included in PCV13, with serotype 19 F 
being the most common. Respiratory allergies as well as overall co-
morbidities were more common in subjects who were positive for only 
non-PCV13 serotypes compared with negative subjects and those who 
were carriers of only PCV13 serotypes. 
Conclusions: 
Although this study included a relatively small number of subjects and 
has been performed in a limited geographic setting, results showed 
that pneumococcal colonization in older people is common, and the 
monitoring of carriers can offer useful information about the 
circulation of this pathogen among older people and the potential 
protective effect of pneumococcal vaccines. Because the colonization 
in most cases involves the strains that are included in PCV13, this 
vaccine could be useful in the prevention of pneumococcal infections 
in the overall population of older people. In subjects with respiratory 
allergies and in those with co-morbidities, the addition of the PPV23 
to PCV13 should be recommended. Due to the low vaccination 
coverage, urgent educational programmes are required to inform older 
adults and their medical doctors of the risks of pneumococcal 
infection and the efficacy and safety of the available pneumococcal 
vaccines. 
5. Measurement of lipocalin-2 and syndecan-4 levels to differentiate 
bacterial from viral infection in children with community-
acquired pneumonia. 
Esposito S, Bianchini S, Gambino M, Madini B, Di Pietro G, 
Umbrello G, Presicce ML, Ruggiero L, Terranova L, Principi N. 
BMC Pulm Med. 2016 Jul 20;16(1):103. doi: 10.1186/s12890-016-
0267-4. 
Abstract: 
Background: 
In this study, we evaluated the lipocalin-2 (LIP2) and syndecan-4 
(SYN4) levels in children who were hospitalized for radiologically 
confirmed CAP in order to differentiate bacterial from viral infection. 
The results regarding the LIP2 and SYN4 diagnostic outcomes were 
compared with the white blood cell (WBC) count and C reactive 
protein (CRP) levels. 
Methods: 
A total of 110 children <14 years old who were hospitalized for 
radiologically confirmed CAP were enrolled. Serum samples were 
obtained upon admission and on day 5 to measure the levels of LIP2, 
SYN4, and CRP as well as the WBC. Polymerase chain reaction of the 
respiratory secretions and tests on blood samples were performed to 
detect respiratory viruses, Streptococcus pneumoniae, and 
Mycoplasma pneumoniae. 
Results: 
CAP was considered to be due to a probable bacterial infection in 74 
children (67.3 %) and due to a probable viral infection in 16 children 
(14.5 %). Overall, 84 children (76.4 %) were diagnosed with severe 
CAP. The mean values of the WBC count and the LIP2 and SYN4 
levels did not differ among the probable bacterial, probable viral, and 
undetermined cases. However, the CRP serum concentrations were 
significantly higher in children with probable bacterial CAP than in 
those with probable viral disease (32.2 ± 55.5 mg/L vs 
9.4 ± 17.0 mg/L, p < 0.05). The WBC count was the best predictor of 
severe CAP, but the differences among the studied variables were 
marginal. The WBC count was significantly lower on day 5 in 
children with probable bacterial CAP (p < 0.01) and in those with an 
undetermined etiology (p < 0.01). The CRP and LIP2 levels were 
significantly lower 5 days after enrollment in all of the studied groups, 
independent of the supposed etiology of CAP (p < 0.01 for all 
comparisons). No statistically significant variation was observed for 
SYN4. 
Conclusions: 
Measuring the LIP2 and SYN4 levels does not appear to solve the 
problem of the poor reliability of routine laboratory tests in defining 
the etiology and severity of pediatric CAP. Currently, the CRP levels 
and WBC, when combined with evaluation of clinical data, can be 
used to limit the overuse of antibiotics as much as possible and to 
provide the best treatment to the patient. 
6. Serotypes not included in 13-valent pneumococcal vaccine as 
causes of acute otitis media with spontaneous tympanic 
membrane perforation in a geographic area with high vaccination 
coverage. 
Marchisio P, Esposito S, Picca M, Baggi E, Terranova L, Orenti A, 
Biganzoli E, Principi N; Milan AOM Study Group. 
Pediatr Infect Dis J. 2017 May;36(5):521-523.  
doi: 10.1097/INF.0000000000001485. 
Abstract: 
In 177 children living in an area with high 13-valent pneumococcal 
conjugate vaccine 13 coverage, who had acute otitis media 
complicated with spontaneous tympanic membrane perforation, 
Streptococcus pneumoniae was identified in the middle ear fluid of 48 
(27.1%) subjects, with 37 (77.1%) cases caused by non-pneumococcal 
conjugate vaccine 13 serotypes. 
7. Acute flaccid myelitis associated with enterovirus-D68 infection in 
an otherwise healthy child. 
Esposito S, Chidini G, Cinnante C, Napolitano L, Giannini 
A, Terranova L, Niesters H, Principi N, Calderini E. 
Virol J. 2017 Jan 11;14(1):4. doi: 10.1186/s12985-016-0678-0. 
Abstract: 
Background: 
Reporting new cases of enterovirus (EV)-D68-associated acute flaccid 
myelitis (AFM) is essential to understand how the virus causes 
neurological damage and to characterize EV-D68 strains associated 
with AFM. 
Case presentation: 
A previously healthy 4-year-old boy presented with sudden weakness 
and limited mobility in his left arm. Two days earlier, he had an upper 
respiratory illness with mild fever. At admission, his physical 
examination showed that the child was febrile (38.5 °C) and alert but 
had a stiff neck and weakness in his left arm, which was hypotonic 
and areflexic. Cerebrospinal fluid (CSF) examination showed a mild 
increase in white blood cell count (80/mm3, 41% neutrophils) and a 
slightly elevated protein concentration (76 gm/dL). Bacterial culture 
and molecular biology tests for detecting viral infection in CSF were 
negative. The patient was then treated with intravenous ceftriaxone 
and acyclovir. Despite therapy, within 24 h, the muscle weakness 
extended to all four limbs, which exhibited greatly reduced mobility. 
Due to his worsening clinical prognosis, the child was transferred to 
our Pediatric Intensive Care Unit; at admission he was diagnosed with 
acute flaccid paralysis of all four limbs. Brain magnetic resonance 
imaging (MRI) was negative, except for a focal signal alteration in the 
dorsal portion of the medulla oblongata, also involving the pontine 
tegmentum, whereas spine MRI showed an extensive signal alteration 
of the cervical and dorsal spinal cord reported as myelitis. Signal 
alteration was mainly localized in the central grey matter, most likely 
in the anterior horns. Molecular biology tests performed on 
nasopharyngeal aspirate and on bronchoalveolar lavage fluid were 
negative for bacteria but positive for EV-D68 clade B3. 
Plasmapheresis was performed and corticosteroids and intravenous 
immunoglobulins were administered. After 4 weeks of treatment, the 
signs and symptoms of AFM were significantly reduced, although 
some weakness and tingling remained in the patient's four limbs. MRI 
acquired after 3 weeks showed that the previously reported alterations 
were no longer present. 
Conclusion: 
This case suggests that EV-D68 is a neurotropic agent that can cause AFM 
and strains are circulating in Europe. EV-D68 disease surveillance is 
required to better understand EV-D68 pathology and to compare various 
strains that cause AFM. 
8. Prospective evaluation of the aetiology of acute otitis media with 
spontaneous tympanic membrane perforation. 
Marchisio P, Esposito S, Picca M, Baggi E, Terranova L, Orenti A, 
Biganzoli E, Principi N; Milan AOM Study Group. 
Clin Microbiol Infect. 2017 Jul;23(7):486.e1-486.e6.  
doi: 10.1016/j.cmi.2017.01.010. 
Abstract: 
Objectives: 
To evaluate the aetiological role of the main bacterial pathogens 
associated with acute otitis media (AOM) in children with AOM and 
spontaneous tympanic membrane perforation (STMP). 
Methods: 
Between 1 May 2015 and 30 April 2016, 177 children, aged 6 months 
to 7 years, with AOM complicated by STMP within 12 h were 
prospectively enrolled. Middle ear fluid (MEF) was tested by real-
time PCR for Streptococcus pneumoniae, non-typeable Haemophilus 
influenzae, Streptococcus pyogenes, Moraxella catarrhalis and 
Staphylococcus aureus. 
Results: 
Among the 177 children with AOM and STMP, 92/100 (92.0%) of 
those with recurrent AOM and 13/77 (16.9%) without recurrent AOM 
had recurrent STMP (p <0.001). A single pathogen was identified in 
70 (39.5%) MEF samples, whereas two, three and four bacteria were 
detected in 54 (30.5%), 20 (11.3%), and 7 (4.0%) cases, respectively. 
Non-typeable H. influenzae was the most common and was identified 
in 90 children (50.8%), followed by M. catarrhalis (62 cases, 35.0%) 
and S. pneumoniae (48 cases, 27.1%). Non-typeable H. influenzae 
was the most frequent pathogen in children with co-infections. 
Children with co-infections, including non-typeable H. influenzae, had 
significantly more frequent recurrent AOM (adjusted OR 6.609, 95% 
CI 1.243-39.096, p 0.029). 
Conclusions: 
Recurrent AOM episodes appear to be associated with an increased 
risk of AOM with STMP. In AOM with STMP, non-typeable 
H. influenzae is detected at a high frequency, especially in children 
with recurrent STMP and often in association with other pathogens. 
9. Severe pneumonia caused by Influenza A (H1N1) virus 
successfully managed with extracorporeal life support in a 
comorbid former preterm infant. 
Raffaeli G, Cavallaro G, Pugni L, Leva E, Artoni A, Neri S, Baracetti 
C, Cotza M, Gentilino V, Terranova L, Esposito S, Mosca F. 
Int J Environ Res Public Health. 2017 Mar 31;14(4). pii: E360.  
doi: 10.3390/ijerph14040360. 
Abstract: 
Influenza A (H1N1) virus infection is a global health burden, leading 
to significant pediatric morbidity and mortality. Prematurity, young 
age and comorbidities are important risk factors for unfavorable 
outcomes. Preventive strategies, such as healthcare workers and 
household contacts vaccination as well as the implementation of 
infection control practices during the epidemic season, are crucial to 
protect the most vulnerable populations. Early diagnosis, timely 
administration of antiviral drugs and supportive therapy are crucial to 
lead to a complete recovery. When conventional treatment fails, 
extracorporeal life support (ECLS) may be employed. In neonates and 
young infants, this high-tech support is burdened by specific technical 
complexity. Despite the potential risks related to this aggressive 
approach, ECLS is a life-saving procedure in 65% of pediatric viral 
pneumonia and in 73% of sepsis cases. Here, we report the successful 
outcome of a 51-day formerly preterm infant, suffering from a 
surgical necrotizing enterocolitis (NEC), complicated with hospital-
acquired pneumonia due to influenza A (H1N1) virus. She developed 
a severe respiratory failure, unresponsive to conventional therapy, and 
successfully treated with ECLS. To our knowledge, this is the first 
report on the use of ECLS in a formerly preterm infant, suffering from 
NEC complicated by influenza A (H1N1) virus infection. 
10. Pertussis-associated persistent cough in previously vaccinated 
children. 
Principi N, Litt D, Terranova L, Picca M, Malvaso C, Vitale C, Fry 
NK, Esposito S; The Italian Pertussis Group For Persistent Cough In 
Children. 
J Med Microbiol. 2017 Nov;66(11):1699-1702.  
doi: 10.1099/jmm.0.000607.  
Abstract: 
To evaluate the role of Bordetella pertussis infection, 96 otherwise 
healthy 7- to 17-year-old subjects who were suffering from a cough 
lasting from 2 to 8 weeks were prospectively recruited. At enrolment, 
a nasopharyngeal swab and an oral fluid sample were obtained to 
search for pertussis infection by the detection of B. pertussis DNA 
and/or an elevated titre of anti-pertussis toxin IgG. Evidence of 
pertussis infection was found in 18 (18.7 %; 95 % confidence interval, 
11.5-28.0) cases. In 15 cases, the disease occurred despite booster 
administration. In two cases, pertussis was diagnosed less than 2 years 
after the booster injection, whereas in the other cases it was diagnosed 
between 2 and 9 years after the booster dose. This study used non-
invasive testing to show that pertussis is one of the most important 
causes of long-lasting cough in school-age subjects. Moreover, the 
protection offered by acellular pertussis vaccines currently wanes 
more rapidly than previously thought. 
11. Neutrophil elastase in bronchiectasis.  
Gramegna A, Amati F, Terranova L, Sotgiu G, Tarsia P, Miglietta D, 
Calderazzo MA, Aliberti S, Blasi F. 
Respir Res. 2017 Dec 19;18(1):211. doi: 10.1186/s12931-017-0691-x. 
Review. 
Abstract: 
The role of neutrophil elastase (NE) is poorly understood in 
bronchiectasis because of the lack of preclinical data and so most of 
the assumptions made about NE inhibitor potential benefit is based on 
data from CF. In this context, NE seems to be a predictor of long-term 
clinical outcomes and a possible target of treatment. In order to better 
evaluate the role of NE in bronchiectasis, a systematic search of 
scientific evidence was performed.Two investigators independently 
performed the search on PubMed and included studies published up to 
May 15, 2017 according to predefined criteria. A final pool of 31 
studies was included in the systematic review, with a total of 2679 
patients. For each paper data of interest were extracted and reported in 
table.In this review sputum NE has proved useful as an inflammatory 
marker both in stable state bronchiectasis and during exacerbations 
and local or systemic antibiotic treatment. NE has also been associated 
with risk of exacerbation, time to next exacerbation and all-cause 
mortality. This study reviews also the role of NE as a specific target of 
treatment in bronchiectasis. Inhibition of NE is at a very early stage 
and future interventional studies should evaluate safety and efficacy 
for new molecules and formulations. 
 
12. Neisseria meningitidis serogroup B carriage by adolescent and 
young adults living in Milan, Italy: prevalence of strains 
potentially covered by the presently available meningococcal B 
vaccines.  
Terranova L, Principi N, Bianchini S, Di Pietro G, Umbrello G, 
Madini B, Esposito S. 
Hum Vaccin Immunother. 2018 Mar 27:1-16. doi: 
10.1080/21645515.2018.1450121. 
Abstract: 
Recently, two vaccines against meningococcal serogroup B (MenB) 
have been developed. They are prepared according to the reverse 
vaccinology approach and contain 4 (4CMenB) and 2 (MenB-FHbp) 
cross-reactive surface proteins. In Italy 4CMenB vaccine has been 
included in the official vaccination schedule only recently and 
recommended only for infants and toddlers, whereas MenB-FHbp is 
not licensed. In order to collect information about the present carriage 
of Neisseria meningitidis serogroup B (MenB) in Italian adolescents 
and to evaluate the potential protection offered by the presently 
available MenB vaccines, 2,560 otherwise healthy, high school 
students aged 14-21 years (907 males, 35.4%, median age 16.2 years) 
were enrolled in Milan, Italy. A swab to collect posterior pharynx 
secretions was collected from each subject and meningococcal 
identification, serogrouping, multilocus sequence typing analysis, 
sequence alignments and phylogenetic analysis were performed. A 
total of 135 (5.3%) adolescents were meningococcal carriers. Strains 
belonging to serogroup B were the most common (n = 58; 2.3%), 
followed by MenY (n = 32; 1.2%), MenC (n = 7; 0.3%), MenW (n = 
6; 0.3%) and MenX (n = 5; 0.2%). The remaining bacteria were not 
capsulated. The identified MenB strains belonged to eleven clonal 
complexes (CCs): ST-162 CC (n = 12; 20.7%), ST-865 CC (n = 12; 
20.7%), ST-41/44/Lin.3 CC (n = 11; 19.0%), ST-35 CC (n = 6; 
10.3%), ST-32/ET-5 CC (n = 4; 6.9%), ST-269 CC (n = 3; 5.2%), ST-
213 CC (n = 2; 3.4%), ST-198 CC (n = 1; 1.7%), ST-461 CC (n = 1; 
1.7%), ST-549 CC (n = 1; 1.7%), and ST-750 CC (n = 1; 1.7%). This 
study showed that MenB was the most commonly carried 
meningococcal serogroup found in adolescents living in Milan, Italy. 
The MenB vaccines presently licensed could have theoretically 
induced the production of antibodies effective against the greatest part 
of the identified MenB strains (100% in the case of 4CMenB and 95% 
in case of MenB-FHbp) Monitoring carriage remains essential to 
evaluate MenB circulation, but further studies are necessary to 
evaluate the effect on carriage and the final efficacy of both new 
MenB vaccines. 
 
13. Staphylococcus aureus colonization and risk of surgical site 
infection in children undergoing clean elective surgery: A cohort 
study. 
Esposito S, Terranova L, Macchini F, Bianchini S, Biffi G, Viganò 
M, Pelucchi C, Leva E, Principi N.  
Medicine (Baltimore). 2018 Jul;97(27):e11097. doi: 
10.1097/MD.0000000000011097. 
Abstract:  
Staphylococcus aureus persistently colonizes the skin and 
nasopharynx of approximately 20% to 30% of individuals, with the 
highest rates in younger children. To avoid clinical problems for 
carriers and the spread of S aureus to other hospitalized patients, 
screening and decolonization of carriers undergoing surgery has been 
recommended. However, the best approach to patients undergoing 
clean surgery is not precisely defined. To evaluate whether children 
carrying S aureus admitted to the hospital for clean elective surgery 
have an increased risk of postoperative surgical infections, 393 infants 
and children (77.1% males; mean age ± standard deviation, 7.6 ± 4.5 
years) who were scheduled for clean elective surgery procedures were 
evaluated for S aureus carriage on the day of intervention and 5 days 
after it. Both anterior nares and pharyngeal swabs were collected. S 
aureus was identified using the RIDAGENE methicillin-resistant S 
aureus (MRSA) system (R-Biopharm AG, Darmstadt, Germany), 
according to the manufacturer's instructions. At admission, 138 
(35.1%) children screened positive for S aureus. MRSA was identified 
in 40 (29.0% of S aureus positive subjects) cases. The carriage rates of 
S aureus and MRSA varied considerably with age, and in children <2 
years old the rate was significantly lower than in any other age group 
(P < .05). Surgical site infection was demonstrated in 4 out of 109 
(3.7%) children who were initially colonized by S aureus and in 5 out 
of 201 (2.5%) children with a negative screening, without any 
statistically significant difference between groups (P = .72). None of 
these children had MRSA. These results seem to suggest that children 
undergoing clean elective surgery do not need to be screened for S 
aureus colonization because, although positive, they have no increased 
risk of surgical site infection. Following this statement, preoperative 
procedures should be simplified with relevant advantages from a 
clinical, social, and economic point of view. 
14. When and out rouling cystic fibrosis in adults patients with 
bronchiectasis. 
Gramegna A, Aliberti S, Seia M, Porcaro L, Bianchi V, Castellani C, 
Melotti P, Sorio C, Consalvo E, Franceschi E, Amati F, Contarini M, 
Gaffuri M, Roncoroni L, Vigone B, Bellofiore A, Del Monaco C, 
Oriano M, Terranova L, Patria MF, Marchisio P, Assael BM, Blasi 
F. 
Abstract:  
Bronchiectasis is the final result of different processes and most of the 
guidelines advocate for a careful evaluation of those etiologies which 
might be treated or might change patients' management, including 
cystic fibrosis (CF). CFTR mutations have been reported with higher 
frequency in bronchiectasis population. Although ruling out CF is 
considered as a main step for etiological screening in bronchiectasis, 
CF testing lacks of a standardized approach both from a research and 
clinical point of view. In this review a list of most widely used tests in 
CF is provided. Exclusion of CF is imperative for patients with 
bronchiectasis and CFTR testing should be implemented in usual 
screening for investigating bronchiectasis etiology. Physicians taking 
care of bronchiectasis patients should be aware of CFTR testing and 
its limitations in the adult population. Further studies on CFTR 
expression in human lung and translational research might elucidate 
the possible role of CFTR in the pathogenesis of bronchiectasis. 
15. The Italian registry of pulmonary non-tubercolus mycobacteria - 
IRENE: the study protocol. 
Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, 
Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, 
Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato 
B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, 
Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, 
Previdi G, Blasi F; IRENE Network. 
Abstract:  
Background: 
A substantial increase in pulmonary and extra-pulmonary diseases due 
to non-tuberculous mycobacteria (NTM) has been documented 
worldwide, especially among subjects suffering from chronic 
respiratory diseases and immunocompromised patients. Many 
questions remain regarding the epidemiology of pulmonary disease 
due to NTM (NTM-PD) mainly because reporting of NTM-PD to 
health authorities is not mandated in several countries, including Italy. 
This manuscript describes the protocol of the first Italian registry of 
adult patients with respiratory infections caused by NTM (IRENE). 
Methods: 
IRENE is an observational, multicenter, prospective, cohort study 
enrolling consecutive adult patients with either a NTM respiratory 
isolate or those with NTM-PD. A total of 41 centers, including mainly 
pulmonary and infectious disease departments, joined the registry so 
far. Adult patients with all of the following are included in the 
registry: 1) at least one positive culture for any NTM species from any 
respiratory sample; 2) at least one positive culture for NTM isolated in 
the year prior the enrolment and/or prescribed NTM treatment in the 
year prior the enrolment; 3) given consent to inclusion in the study. 
No exclusion criteria are applied to the study. Patients are managed 
according to standard operating procedures implemented in each 
IRENE clinical center. An online case report form has been developed 
to collect patients' demographics, comorbidities, microbiological, 
laboratory, functional, radiological, clinical, treatment and outcome 
data at baseline and on an annual basis. An IRENE biobank has also 
been developed within the network and linked to the clinical data of 
the registry. 
Conclusions: 
IRENE has been developed to inform the clinical and scientific 
community on the current management of adult patients with NTM 
respiratory infections in Italy and acts as a national network to 
increase the disease's awareness. 
16. How to Process Sputum Samples and Extract Bacterial DNA for 
Microbiota Analysis. 
Terranova L, Oriano M, Teri A, Ruggiero L, Tafuro C, Marchisio P, 
Gramegna A, Contarini M, Franceschi E, Sottotetti S, Cariani L, 
Bevinino A, Chalmers JD, Aliberti S, Blasi F. 
Abstract:  
Different steps and conditions for DNA extraction for microbiota 
analysis in sputum have been reported in the literature. We aimed at 
testing both dithiothreitol (DTT) and enzymatic treatments of sputum 
samples and identifying the most suitable DNA extraction technique 
for the microbiota analysis of sputum. Sputum treatments with and 
without DTT were compared in terms of their median levels and the 
coefficient of variation between replicates of both DNA extraction 
yield and real-time PCR for the 16S rRNA gene. Treatments with and 
without lysozyme and lysostaphin were compared in terms of their 
median levels of real-time PCR for S. aureus. Two enzyme-based and 
three beads-based techniques for DNA extraction were compared in 
terms of their DNA extraction yield, real-time PCR for the 16S rRNA 
gene and microbiota analysis. DTT treatment decreased the coefficient 
of variation between replicates of both DNA extraction yield and real-
time PCR. Lysostaphin (either 0.18 or 0.36 mg/mL) and lysozyme 
treatments increased S. aureusdetection. One enzyme-based kit 
offered the highest DNA yield and 16S rRNA gene real-time PCR 
with no significant differences in terms of alpha-diversity indexes. A 
condition using both DTT and lysostaphin/lysozyme treatments along 
with an enzymatic kit seems to be preferred for the microbiota 
analysis of sputum samples. 
 
 
 
 
 
 
 
 
 
8. PhD courses  
1. Introduzione alla statistica per l’epidemiologia e la sanità pubblica.  
Prof. Bossi, 11, 14 Apr 2016 
2. Le strategie di sanità pubblica in ambito vaccinale. 
Prof. Romanò, Castaldi, Mapelli 10, 17, 24 Feb, 4, 31 May 2016 
3. Misure di associazione in epidemiologia. 
Prof. Decarli 24 May, 27 Jun 2016 
4. Open access – open data e il mondo delle pubblicazioni. 
Competenze trasversali 17 Jun 2016 
5. Disegno e analisi di studi caso-controllo. 
Prof. La Vecchia 10-11 May 2016 
6. Elementi di valutazione del rischio chimico. 
Prof. Moretto 23, 24, 30 Jun, 1 Jul 2016 
7. Come scrivere un progetto di ricerca-parte 1. Le 100 cose che avrei 
voluto sapere quando ero un dottorando. 
Competenze trasversali 22 Feb 2017 
8. General linear model and experimental design using “R” 
Prof. Micciolo 27, 28, 29, 30, 31 Mar 2017 
9. Come scrivere un progetto di ricerca-parte 2. Le 100 cose che avrei 
voluto sapere quando ero un dottorando. 
Competenze trasversali 16 Jun 2017 
10. Analisi della sopravvivenza. 
Prof. Ambrogi, Boracchi, Biganzoli 19, 20, 21, 22, 23 Feb 2018 
11. Tutelare e valorizzare sul mercato i risultati della ricerca in UniMi. 
Competenze trasversali 8 Mar 2018 
12. Valorizzare creando impresa: fare spin off in UniMi (prima parte). 
Competenze trasversali 20 Apr 2018 
13. Revisioni sistematiche con meta-analisi: metodi statistici ed 
interpretazione dei risultati. 
Prof. Casazza 22-23 May 2018 
14. Valorizzare creando impresa: fare spin off in UniMi (seconda parte). 
Competenze trasversali 25 May 2018 
15. Costruire un profilo professionale attraverso le competenze 
trasferibili. Quali possibilità per i dottori di ricerca? 
Competenze trasversali 20 Jun 2018 
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